Cargando…
Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry
PURPOSE: For most disease sites, level 1 evidence is lacking for proton beam therapy (PBT). By identifying target populations that would benefit most from PBT, prospective registries could overcome many of the challenges in clinical trial enrollment. Herein, we report clinical outcomes of patients t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767257/ https://www.ncbi.nlm.nih.gov/pubmed/35071826 http://dx.doi.org/10.1016/j.adro.2021.100767 |
_version_ | 1784634698163552256 |
---|---|
author | Jongen, Aurélien Charlier, Florian Baker, Kelsey Chang, John Hartsell, William Laramore, George Mohindra, Pranshu Moretti, Luigi Redman, Mary Rosen, Lane Tsai, Henry Van Gestel, Dirk Vargas, Carlos Rengan, Ramesh |
author_facet | Jongen, Aurélien Charlier, Florian Baker, Kelsey Chang, John Hartsell, William Laramore, George Mohindra, Pranshu Moretti, Luigi Redman, Mary Rosen, Lane Tsai, Henry Van Gestel, Dirk Vargas, Carlos Rengan, Ramesh |
author_sort | Jongen, Aurélien |
collection | PubMed |
description | PURPOSE: For most disease sites, level 1 evidence is lacking for proton beam therapy (PBT). By identifying target populations that would benefit most from PBT, prospective registries could overcome many of the challenges in clinical trial enrollment. Herein, we report clinical outcomes of patients treated with PBT for locally advanced non-small cell lung cancer (LA-NSCLC). METHODS AND MATERIALS: Data were obtained from the multi-institutional prospective database of the Proton Collaborative Group (PCG). Inclusion criteria of our study were stage III de novo or recurrent LA-NSCLC, use of PBT, and availability of follow-up data. Overall survival (OS) time was calculated from the start of treatment until death or last follow-up. Kaplan-Meier curves were generated for groups of interest and compared with log-rank tests. Cox regression modeling was used to evaluate the multivariate association between selected covariates and OS. RESULTS: A total of 195 patients were included in the analysis. PBT was given with a median equivalent dose in 2 Gy fractions (EQD2) of 63.8 Gy (relative biological effectiveness). Pencil beam scanning was used in 20% of treatments. Treatment-related grade 3 adverse events were rare: 1 pneumonitis, 2 dermatitis, and 3 esophagitis. No grade 4 events were reported. Two cardiac-related grade 5 events occurred in patients with multiple risk factors. The median follow-up time for living patients was 37.1 months and the median OS was 19.0 months. On multivariate analysis, good performance status (hazard ratio, 0.27; [95% confidence interval, 0.15-0.46]; P < .0001), pencil beam scanning use (0.55; [0.31-0.97]; P = .04), and increased EQD2 (0.80; [0.71-0.90] - per 10 Gy increase; P = .0002) were associated with decreased mortality. CONCLUSIONS: PBT appears to yield low rates of adverse events with an OS similar to other retrospective studies on PBT for LA-NSCLC. PBS use and increased EQD2 can potentially improve OS. |
format | Online Article Text |
id | pubmed-8767257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87672572022-01-21 Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry Jongen, Aurélien Charlier, Florian Baker, Kelsey Chang, John Hartsell, William Laramore, George Mohindra, Pranshu Moretti, Luigi Redman, Mary Rosen, Lane Tsai, Henry Van Gestel, Dirk Vargas, Carlos Rengan, Ramesh Adv Radiat Oncol Scientific Article PURPOSE: For most disease sites, level 1 evidence is lacking for proton beam therapy (PBT). By identifying target populations that would benefit most from PBT, prospective registries could overcome many of the challenges in clinical trial enrollment. Herein, we report clinical outcomes of patients treated with PBT for locally advanced non-small cell lung cancer (LA-NSCLC). METHODS AND MATERIALS: Data were obtained from the multi-institutional prospective database of the Proton Collaborative Group (PCG). Inclusion criteria of our study were stage III de novo or recurrent LA-NSCLC, use of PBT, and availability of follow-up data. Overall survival (OS) time was calculated from the start of treatment until death or last follow-up. Kaplan-Meier curves were generated for groups of interest and compared with log-rank tests. Cox regression modeling was used to evaluate the multivariate association between selected covariates and OS. RESULTS: A total of 195 patients were included in the analysis. PBT was given with a median equivalent dose in 2 Gy fractions (EQD2) of 63.8 Gy (relative biological effectiveness). Pencil beam scanning was used in 20% of treatments. Treatment-related grade 3 adverse events were rare: 1 pneumonitis, 2 dermatitis, and 3 esophagitis. No grade 4 events were reported. Two cardiac-related grade 5 events occurred in patients with multiple risk factors. The median follow-up time for living patients was 37.1 months and the median OS was 19.0 months. On multivariate analysis, good performance status (hazard ratio, 0.27; [95% confidence interval, 0.15-0.46]; P < .0001), pencil beam scanning use (0.55; [0.31-0.97]; P = .04), and increased EQD2 (0.80; [0.71-0.90] - per 10 Gy increase; P = .0002) were associated with decreased mortality. CONCLUSIONS: PBT appears to yield low rates of adverse events with an OS similar to other retrospective studies on PBT for LA-NSCLC. PBS use and increased EQD2 can potentially improve OS. Elsevier 2021-09-10 /pmc/articles/PMC8767257/ /pubmed/35071826 http://dx.doi.org/10.1016/j.adro.2021.100767 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Scientific Article Jongen, Aurélien Charlier, Florian Baker, Kelsey Chang, John Hartsell, William Laramore, George Mohindra, Pranshu Moretti, Luigi Redman, Mary Rosen, Lane Tsai, Henry Van Gestel, Dirk Vargas, Carlos Rengan, Ramesh Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry |
title | Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry |
title_full | Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry |
title_fullStr | Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry |
title_full_unstemmed | Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry |
title_short | Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry |
title_sort | clinical outcomes after proton beam therapy for locally advanced non-small cell lung cancer: analysis of a multi-institutional prospective registry |
topic | Scientific Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767257/ https://www.ncbi.nlm.nih.gov/pubmed/35071826 http://dx.doi.org/10.1016/j.adro.2021.100767 |
work_keys_str_mv | AT jongenaurelien clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT charlierflorian clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT bakerkelsey clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT changjohn clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT hartsellwilliam clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT laramoregeorge clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT mohindrapranshu clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT morettiluigi clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT redmanmary clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT rosenlane clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT tsaihenry clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT vangesteldirk clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT vargascarlos clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry AT renganramesh clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry |